Search

Enabling the spread of good research – a day in the life of an Editor-in-Chief

Most conversations with the Editor of a scientific journal usually revolve around the acceptance (hooray!) or rejection (oh no!) of our research work.

Read more

Chairs and Members

Chair (2022–2024 term)Edward Laane

Co-chairs (2022–2024 term)
Esther Natalie Oliva
Sam Salek
Secretary (2022–2024 term)Tatyana Ionova

SWG Executive Board members (2022–2024 term)
Tatiana Ionova, Сhair of Department, St. Petersburg State University Hospital, St.

Read more

Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases

Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte  Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

Chairs and Members

Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)

Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)

SWG Executive Board members and terms:

Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…

Read more

Highlights from the SWG

Joint work with the International Society on Thrombosis and Haemostasis (ISTH), the European Association for Haemophilia and Allied Disorders (EAHAD), and the European Stroke Organisation (ESO) to produce guidance on antithrombotic treatment in patients with hemophilia.

Read more

EHA-RHS-ROHS Hematology Tutorial 2021

EHA in collaboration with the National Hematological Society (RHS) and the Russian Onco-Hematology Society (ROHS) are closely monitoring the developments concerning the Coronavirus (COVID-19), as our priorities lie with the health and safety of our participants and partners.

Read more